AMSBIO: Lentivirus for miRNA Expression and Inhibition
AMSBIO has introduced a range of ready-to-use human and mouse lentivirus products for miRNA and anti-miRNA expression (miRNA inhibition). Lentiviral expression vectors are the most effective vehicles for delivering genetic material to almost any mammalian cell — including non-dividing cells and whole model organisms.
miRNAs are endogenous non-coding RNAs that are highly conserved in mammals and that regulate gene expression post-transcriptionally through innate RNA interference mechanisms. As key players in the fine-tuning of biological networks, miRNAs offer significant diagnostic and prognostic potential as biomarkers not only of fundamental cellular physiology but also of disease etiology and progression.
To study long-term miRNA-induced phenotypes, AMSBIO has developed a range of ready-to-use products for stable expression of the mature miRNA. There are more than 2000 mature miRNA discovered in human and more than 1200 miRNA in mouse so far. miRNA mainly silence or repress gene expression via binding to the complementary sequences of gene coding mRNA. Each miRNA can target multiple genes. It is believed than greater than 60% of mammalian gene expression is regulated by miRNAs, and miRNAs are involved in most biological processes, including a variety of diseases or disorders development.
AMSBIO's range of ready-to-use, anti-miRNA lentivirus (miRNA inhibitors) are produced from the optimally designed anti miRNA lentivectors. The annealed DNA oligonucleotides hairpin duplex encoding the antisense of a specific miRNA sequence are cloned under a constitutive human U6 promoter or under an optional inducible human H1 promoter. AMSBIO’s anti-miRNA lentivector was carefully designed for highest anti-miRNA expression level with precise promoter transcription position, and to favor the antisense strand for RISC complex processing.
Anti-miRNA or miRNA inhibitors are short RNA molecules complementary to the mature miRNA sequence. Anti miRNA specifically binds to endogenous miRNA and it inhibits or down-regulates miRNA activity. Therefore, anti-miRNA is a great tool for the loss of function research of any specific miRNAs. miRNA inhibitors also show potential as therapeutic agents for some biological malfunctions.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.